[Adults] {Spam? 3.10} Nuvilex, Inc. Now Restrains Use of Live Cell Encapsulation Technology for Any Type of Can_cer by Any Body

[Investment Info]

Nuvilex Inc. (NVLX)

Nuvilex, Inc. Now Manages
Usage of Live Cell Encapsulation Technology for Any
Type of Can_cer by Any Organization


When Nuvilex, Inc. (OTCQB: NVLX) gained
all of the shares of Bio Blue Bird AG from SG Austria Pri-vate Limited what
may have been confused in all the legal lingo of
last week’s procurement is that
Nuvilex now commands the use of this technology as it
correlates to its usage in any
therapy, of any version of can_cer, by any entity.
This update alone could not only
radically
boost Nuvilex’s pipeline, but could
entice numerous of
big name pharmaceutical and biotech companies to
Nuvilex’s threshold.  The key, of course, is Nuvilex’s
forthcoming Level Three pancreas
can_cer tests.

This is a deal where Nuvilex and
its shareholders win big, and quite
honestly the
change was pure genius and may
show to be valued bil_lions of
dol_lars.  Can_cer is huge business and Nuvilex
carried out what can only be
termed as the barg_ain
of a lifetime.  The organization was able to
secure a deal that permitted
them to “cherry-pick” the exact piece of the pie Nuvilex
needed from a different
entity.   And, what was the precise piece of
the pie Nuvilex went after – Bio Blue Bird AG and,
more relevantly, its
world-wide licenses connected to the live-cell encapsulation platform technology to
cultivate therapies for all can_cer types –
and that’s precisely what the
company got.

75 Arlington Street, Suite 500, Boston,
Massachusetts 02116 United States


The use of research materials circulated by the auth.or is done at your own
risk. You are encouraged to do your own research before making any
investment decision in regards to the secu rity discussed herein. The
author has not been rewarded by any entity in connection with the
distribution of these materials. You should presume that as of the date of
this report or letter, the author, possibly along with or through our
owners, affiliates, employees and/or consultants, (cooperatively referred
to as the author) has a position in all company shares (and/or options of
the shares) covered herein that is consistent with the position set forth
in our report. In connection with NVLX, the author has taken a long
position. Following the disbursement of any report or letter, the author
intends to continue engaging in trnsactns in the secu rity covered herein,
and we may be long, short, and/or neutral at any time hereafter regardless
of our initial position and we preserve the right to procure or trade all
or part of our position at any time without notice. This practice could end
in our trading securities at any time before, during, and/or after the
disbursement of this report.

 Be removed
http://support.futzona.net/unsubscribe.php?M=6588707&C=0a89a74737fe0ab850bde605efc11be4&L=54&N=1312


-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://www.polarhome.com/pipermail/adults/attachments/20130719/0dad9081/attachment.html>